Cancer immunotherapy .net
Information on human tumours 3
tumour type
Nasopharyngeal carcinoma
Data in brief:

Five-year disease-free survival:
8% without local IL-2 (radiation only)
63% with local IL-2

Phase III study is planned

See also press release

Zie ook persbericht
Jacobs et al. (2005) Cancer Immunology, Immunotherapy 54, 792-8
This research will be highlighted in the october 2005 edition of nature clinical practices oncology
tumour type
Interleukin-2 (IL-2)
Mechanism of IL-2 therapy of cancer

Cancers sensitve to IL-2
Surgery and IL-2
Radiotherapy and IL-2
Chemotherapy and IL-2

I want to co-operate (doctors)
Frequently Asked Questions (FAQs)
Information for doctors

Information for patients

I want to support this research or  more information on the EPTI fund supporting this research
Our research is supported by Stichting ter bevordering van het onderzoek in de Experimentele Pathologie en in het bijzonder in de TumourImmunologie. Stichting EPTI, IJselstein, The Netherlands